# Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

> **NCT06706284** · PHASE4 · RECRUITING · sponsor: **Marzieh Salehi** · enrollment: 50 (estimated)

## Conditions studied

- Spinal Cord Injuries
- Type 2 Diabetes

## Interventions

- **DRUG:** Semaglutide Injectable Product
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06706284
- **Lead sponsor:** Marzieh Salehi
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06706284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06706284, "Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06706284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*